Thanks for visiting Scientific Computing World.

You're trying to access an editorial feature that is only available to logged in, registered users of Scientific Computing World. Registering is completely free, so why not sign up with us?

By registering, as well as being able to browse all content on the site without further interruption, you'll also have the option to receive our magazine (multiple times a year) and our email newsletters.

Cresset announces Proximagen has licensed Cresset's Forge and Spark software

Share this on social media:

Cresset, innovative provider of computational chemistry software and services, is pleased to announce that Proximagen, a company focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system (CNS), has licensed Cresset’s Forge and Spark software. These applications provide extensive capabilities in SAR analysis, ligand-based molecular design and bioisosteric replacement.

'Proximagen has successfully used Cresset’s computational chemistry tools in the past to generate pharmacophores from known ligands and to identify novel chemical series by scaffold hopping,' says Dr Ed Savory, Deputy Head of Chemistry at Proximagen. 'We will be using Spark to identify new drug scaffolds and to make bioisosteric core replacements. Both Spark and Forge are now important and valuable components of our drug discovery program.'

'We are delighted that Proximagen have chosen to further the collaboration with Cresset', said Dr David Bardsley, Cresset’s Commercial Director. 'Cresset’s continual striving for outstanding science delivered in usable software is translating into valuable results for our customers.'

Cresset, a provider of computational chemistry software and services, has announced that Proximagen, a company focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system (CNS), has licensed Cresset’s Forge and Spark software.

These applications provide extensive capabilities in SAR analysis, ligand-based molecular design and bioisosteric replacement.

'Proximagen has successfully used Cresset’s computational chemistry tools in the past to generate pharmacophores from known ligands and to identify novel chemical series by scaffold hopping,' says Dr Ed Savory, Deputy Head of Chemistry at Proximagen. 'We will be using Spark to identify new drug scaffolds and to make bioisosteric core replacements. Both Spark and Forge are now important and valuable components of our drug discovery program.'

'We are delighted that Proximagen have chosen to further the collaboration with Cresset, says Dr David Bardsley, Cresset’s Commercial Director. “Cresset’s continual striving for outstanding science delivered in usable software is translating into valuable results for our customers.'

Company: